AC Immune
ACIU
28 hedge funds and large institutions have $45.5M invested in AC Immune in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0.06% less ownership
Funds ownership: 19.17% → 19.11% (-0.06%)
3% less call options, than puts
Call options by funds: $170K | Put options by funds: $176K
4% less capital invested
Capital invested by funds: $47.4M → $45.5M (-$1.83M)
10% less funds holding
Funds holding: 31 → 28 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$203K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$58.6K |
| 3 |
Renaissance Technologies
New York
|
+$21.9K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$19.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$167K |
| 2 |
Millennium Management
New York
|
-$152K |
| 3 |
Morgan Stanley
New York
|
-$49.8K |
| 4 |
Two Sigma Investments
New York
|
-$45.1K |
| 5 |
Squarepoint
New York
|
-$32.6K |
ACIU Hedge Fund Activity: Q3 2023 in Review
28 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q3 2023, worth a combined $45.5M — down 3.9% from $47.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ACIU and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 8 added.
The largest buyer was Avidity Partners Management, adding an estimated $203K. The largest seller was State Street, exiting entirely with an estimated $167K sold.
- 28 institutional investors held AC Immune (ACIU) as of Q3 2023, down from 31 in Q2 2023.
- Funds reported $45.5M of AC Immune stock for Q3 2023, down 3.9% quarter-over-quarter.
- 3 funds opened new AC Immune positions in Q3 2023 and 6 closed out, a net change of -3 holders.
- The largest AC Immune buyer in Q3 2023 was Avidity Partners Management, an estimated $203K added.
- The largest AC Immune seller in Q3 2023 was State Street, an estimated $167K sold.
Based on aggregated 13F filings for Q3 2023.